Fifth Amendment to Credit Agreement and GuarantyCredit Agreement and Guaranty • November 7th, 2022 • Agile Therapeutics Inc • Pharmaceutical preparations • New York
This Fifth Amendment to Credit Agreement and Guaranty (herein, this “Agreement”) is entered into as of July 25, 2022 (the “Fifth Amendment Effective Date”), by and among Agile Therapeutics, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto (each a “Lender” and collectively, the “Lenders”) and Perceptive Credit Holdings III, LP, a Delaware limited partnership, as a lender and as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).
AMENDMENT NO. 1 TO MANUFACTURING AND COMMERCIALIZATION AGREEMENTManufacturing and Commercialization Agreement • November 7th, 2022 • Agile Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to Manufacturing and Commercialization Agreement (“Amendment”) is made and entered into as of July 25, 2022 (“Amendment Effective Date”), by and between Corium, Inc., a Delaware corporation having its principal place of business at 4558 50th Street, S.E., Grand Rapids, MI 49512, including its Affiliates (“Corium”), and Agile Therapeutics, Inc., a Delaware corporation, having its principal place of business at 500 College Rd. East Suite 310 Princeton, NJ 08540, including its Affiliates (“Agile”), and amends that certain Manufacturing and Commercialization Agreement (the “Agreement”), entered into as of April 30, 2020, by and between Corium and Agile. All capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to them in the Agreement.
